Natco Pharma Limited has informed the Exchange regarding Appointment of Mr K Srinivasa Rao as Executive Vice President - Pharma Division of the company w.e.f. February 12, 2026.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Smallcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma announced three senior management changes effective February 12-13, 2026. The company's CFO, Mr. S.V.V.N. Appa Rao, retired (superannuated) after his tenure ended with the close of business on February 12, 2026. He has been replaced by Mr. Amit Parekh, who was internally promoted from Executive Vice President – Finance & Accounts. Mr. Parekh has over 23 years of experience, including a prior stint at Dr. Reddy's Laboratories in finance and digital transformation roles. Separately, Mr. Kalakuntla Srinivasa Rao (25+ years of experience) was appointed as Executive Vice President – Pharma Division, with prior leadership roles at MSN Laboratories and Lupin Limited. The changes were approved by the Board and disclosed under SEBI Listing Regulations.
This is a planned, orderly leadership transition. The internal CFO promotion (Amit Parekh) suggests continuity in financial strategy and is generally viewed positively by investors. The new EVP – Pharma Division hire strengthens operational leadership for the pharma business.